文章核心观点 - 公司第二季度2024年收入预计在1550万美元至1600万美元之间,同比增长双位数百分比 [1] - 公司重申到2025年第二季度实现年化运营收入约7500万美元,年化运营EBITDASO1约2000万美元的财务指引 [2][7] - 公司与英国医疗科学公司MedScience签署分销协议,涵盖临床化学、传染病和自身免疫产品 [3][4][6] 公司概况 - 公司是一家专注于人体诊断和糖尿病管理解决方案的商业阶段生物技术公司,包括可穿戴生物传感器 [10] - 公司开发、收购、制造和销售诊断系统,包括试剂和仪器,用于临床实验室和现场诊断市场,最近还进入了可穿戴生物传感器行业 [10] - 公司产品用于检测传染病,并量化血红蛋白A1c和其他化学参数的水平 [10] - 公司在美国直接销售,并通过遍布全球75个国家的国际分销商和战略合作伙伴网络进行销售 [10] MedScience公司概况 - MedScience是Pharmed集团的一家子公司,是英国领先的医疗和科学设备、耗材和服务提供商 [11] - 公司与全球领先制造商签有独家分销协议,为实验室、医疗和科学服务提供商提供最先进的产品 [11] - 公司在英国拥有现代化的总部办公室、仓储和内部维修团队,为客户提供全面的支持 [11]

DUBLIN, July 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of Louise Tallon as Chief Financial Officer (“CFO”). Louise will join Trinity Biotech in August 2024. Des Fitzgerald, who has acted as interim CFO since December 2023 will continue as interim CFO until late July 2024. Commenting on the appointment, John Gillard, CEO ...

DUBLIN, July 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of Louise Tallon as Chief Financial Officer (“CFO”). Louise will join Trinity Biotech in August 2024. Des Fitzgerald, who has acted as interim CFO since December 2023 will continue as interim CFO until late July 2024. Commenting on the appointment, John Gillard, CEO ...

DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced steps to advance its next generation continuous glucose monitoring ("CGM") solution towards market launch. Since acquiring the CGM technology earlier in the year, Trinity Biotech has been working on further innovations and improvements to the original device. The Company has now rece ...

DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced steps to advance its next generation continuous glucose monitoring (“CGM”) solution towards market launch. Since acquiring the CGM technology earlier in the year, Trinity Biotech has been working on further innovations and improvements to the original device. The Company has now rec ...

DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024. Management plans to host meetings with key stakeholders and potential partners as it works to advance the ...

DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024. Management plans to host meetings with key stakeholders and potential partners as it works to advance th ...

DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring (“CGM”) microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company’s stakeholders with key insights into the Company’s vision for the development of the next generation of its recently acquired CGM bio ...

DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring ("CGM") microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company's stakeholders with key insights into the Company's vision for the development of the next generation of its recently acquired CGM bios ...

财务数据和关键指标变化 - 第一季度收入为1470万美元,与上年同期相比基本持平 [70] - Point-of-Care业务收入增长38.5%至300万美元,主要由于TrinScreen HIV检测销售增加 [71] - 临床实验室业务收入下降7.6%至1170万美元,主要由于之前报告的移植检测业务的损失 [72] - 毛利率为37.6%,与上年同期持平,但预计随着TrinScreen HIV销售占比提高,整体毛利率将有所下降 [73][74] - 研发费用基本持平,与收购Waveform资产后持续推进CGM项目开发相关 [76] - 销售及管理费用下降13.5%至750万美元,主要由于去年下半年的人员优化和其他成本节约措施 [77] - 经营亏损3百万美元,较上年同期减少23% [78] - 净亏损3.3百万美元,较上年同期减少47% [81] - EBITDASO亏损1.5百万美元,较上年同期减少25% [81] 各条业务线数据和关键指标变化 - Point-of-Care业务收入增长38.5%,主要由于TrinScreen HIV检测销售增加 [71] - 临床实验室业务中,血红蛋白业务收入增长6.4%,但被移植检测业务的下降所抵消 [72] - 公司正在推进血红蛋白业务的制造成本优化,包括仪器制造供应链优化和内部制造流程改进 [73] 各个市场数据和关键指标变化 - TrinScreen HIV检测在非洲市场的销售有所增加,2024年全年预计销售8百万美元 [71][87] - 公司正在积极拓展TrinScreen HIV在其他国家的销售,不仅局限于肯尼亚 [87] 公司战略和发展方向及行业竞争 - 公司正在执行全面转型计划,包括整合离岸制造、优化供应链和集中离岸公司服务,以大幅提升现有业务的盈利能力 [17][20] - 公司收购Waveform的CGM技术,正在开发下一代可持续、可负担的CGM产品,以期进入这一快速增长的市场 [29][32][34] - CGM市场目前由雅培和戴克斯康主导,公司的CGM产品具有可重复使用的传感器和发射器,有望大幅降低成本和减少环境污染 [39][40][47] - 公司正在与软件公司合作,开发基于CGM数据的数字健康和健康管理解决方案 [55][56] 管理层对经营环境和未来前景的评论 - 公司正在成功扩大TrinScreen HIV的产能和销售,并获得了更多订单 [9][10] - 公司正在执行全面转型计划,通过整合离岸制造、优化供应链和集中离岸公司服务等措施,大幅提升现有业务的盈利能力 [17][20] - 公司收购Waveform的CGM技术,正在开发下一代可持续、可负担的CGM产品,以期进入这一快速增长的市场 [29][32][34] - 公司有信心在2025年夏季前进入CGM产品的关键临床试验,并在2025年底前获得欧盟监管批准 [58] 其他重要信息 - 公司收到纳斯达克发出的延期摘牌通知,但公司将寻求听证并保留纳斯达克上市地位 [66][67][69] - 公司在2024年第一季度获得3.6百万美元的一次性贷款修改收益,并将每季度利息费用控制在250万美元左右 [78][79][106] 问答环节重要的提问和回答 问题1 **Jim Sidoti 提问** TrinScreen在2024年的8百万美元销售额是否全部来自肯尼亚市场,还是会拓展到其他国家? [86] **John Gillard 回答** 公司不会透露具体的国家信息,但预计2024年会向肯尼亚以外的其他国家销售TrinScreen产品 [87] 问题2 **Jim Sidoti 提问** TrinScreen产品扩产过程中是否存在一次性成本? [88] **John Gillard 回答** 主要是人员培训和生产效率提升过程中的过渡成本,而非一次性资本支出。公司正在通过自动化、供应链优化等措施来提高TrinScreen的毛利率 [89][90][91] 问题3 **Jim Sidoti 提问** 未来CGM项目的研发支出预计如何变化? [100] **John Gillard 回答** 2024年每季度研发支出预计控制在200万美元以内。2025年随着进入关键临床试验阶段,支出将有所增加,但公司只会在有很高把握产品能通过试验时才会增加投入 [102][103]